HOOKIPA Pharma Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HOOK research report →
Companywww.hookipapharma.com
HOOKIPA Pharma Inc. , a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors.
- CEO
- Malte Peters
- IPO
- 2019
- Employees
- 82
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $14.90M
- P/E
- -0.36
- P/S
- 1.47
- P/B
- 0.53
- EV/EBITDA
- 0.46
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -453.11%
- Net Margin
- -415.28%
- ROE
- -110.98%
- ROIC
- -115.31%
Growth & Income
- Revenue
- $9.70M · -77.93%
- Net Income
- $-13,837,000 · 68.19%
- EPS
- $-1.09 · 68.59%
- Op Income
- $-36,572,000
- FCF YoY
- 85.07%
Performance & Tape
- 52W High
- $1.77
- 52W Low
- $0.81
- 50D MA
- $1.13
- 200D MA
- $0.97
- Beta
- 0.83
- Avg Volume
- 11.54K
Get TickerSpark's AI analysis on HOOK
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 19, 25 | Peters Malte | sell | 25,172 |
| Jul 22, 25 | Peters Malte | sell | 29,176 |
| Jul 22, 25 | Coelho Mary Theresa | sell | 13,609 |
| Jul 22, 24 | Coelho Mary Theresa | other | 69,875 |
| Jul 22, 24 | Peters Malte | other | 108,695 |
| Jul 22, 24 | Cassidy Sean A | other | 9,800 |
| Jul 22, 24 | Cassidy Sean A | other | 0 |
| Jun 17, 24 | Peters Malte | other | 49,000 |
| Jun 17, 24 | van de Winkel Jan | other | 98,000 |
| Jun 17, 24 | Kaufman David Ross | other | 49,000 |
Our HOOK Coverage
We haven't published any research on HOOK yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HOOK Report →